Biophytis SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BPTS Nasdaq 8731 https://www.biophytis.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biophytis SA (ADR)

Biophytis Announces Receipt of Nasdaq Notice - Nov 17th, 2023 10:15 pm
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil - Oct 30th, 2023 5:20 am
Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel - Oct 27th, 2023 9:15 pm
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations - Sep 27th, 2023 9:45 pm
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma - Sep 26th, 2023 11:32 am
Biophytis shares surge 73% following partnership deal with Skyepharma - Sep 25th, 2023 4:09 pm
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) - Sep 25th, 2023 5:30 am
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19 - Sep 19th, 2023 5:40 am
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer - Sep 14th, 2023 5:30 am
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia - Sep 11th, 2023 5:20 am
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York - Sep 4th, 2023 9:30 pm
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project - Aug 16th, 2023 5:15 am
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe - Aug 8th, 2023 5:20 am
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 - Jul 20th, 2023 5:20 am
Biophytis Announces $3.8 Million Registered Direct Offering - Jul 19th, 2023 6:20 am
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound - Jul 18th, 2023 5:20 am
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia - Jul 10th, 2023 5:00 am
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress - Jun 19th, 2023 5:30 am
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted - Jun 16th, 2023 9:20 pm
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June - Jun 5th, 2023 6:20 am